Analysts have been eager to weigh in on the Healthcare sector with new ratings on CVS Health (CVS – Research Report) and Neurocrine (NBIX – Research Report).
CVS Health (CVS)
In a report released yesterday, Ben Hendrix from RBC Capital maintained a Buy rating on CVS Health, with a price target of $84.00. The company’s shares closed last Wednesday at $76.05.
According to TipRanks.com, Hendrix is a 2-star analyst with an average return of
CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $89.43, a 19.0% upside from current levels. In a report issued on January 25, TD Cowen also maintained a Buy rating on the stock with a $99.00 price target.
See today’s best-performing stocks on TipRanks >>
Neurocrine (NBIX)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Neurocrine yesterday and set a price target of $129.00. The company’s shares closed last Wednesday at $136.29, close to its 52-week high of $143.35.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $145.22 average price target, which is a 7.6% upside from current levels. In a report issued on January 31, Mizuho Securities also maintained a Hold rating on the stock with a $116.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CVS:
- A New Cause for Concern: CVS Health Corp Adds a New Corporate Activity and Growth Risk
- CVS Health Corp Earnings Update: Did it Beat Estimate Forecasts?
- CVS Health (NYSE:CVS) Rises after Q4 Earnings Beat
- CVS Health backs FY24 Pharmacy & consumer wellness revenue ‘at least’ $123.4B
- CVS Health backs FY24 Health Services revenue ‘at least’ $169.7B
